NCT01784913View on ClinicalTrials.gov

A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 15, 2013

Primary Completion Date

July 8, 2015

Study Completion Date

October 23, 2020

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

UV1 synthetic peptide vaccine and GM-CSF

Trial Locations (1)

0424

Oslo University Hospital, Oslo

All Listed Sponsors
lead

Ultimovacs ASA

INDUSTRY

NCT01784913 - A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter